Navigation Links
Researchers uncover gene's role in rheumatoid arthritis, findings pave way for new treatments
Date:1/24/2013

ANN ARBOR, Mich. University of Michigan research sheds new light on why certain people are more likely to suffer from rheumatoid arthritis paving the way to explore new treatments for both arthritis and other autoimmune diseases.

The new UMHS research in mice identifies how a specific group of genes works behind the scenes to activate the bone-destroying cells that cause severe rheumatoid arthritis, a debilitating health issue for millions of Americans.

"We believe this could be a significant breakthrough in our understanding of why certain genes are associated with higher risk of rheumatoid arthritis and other autoimmune diseases a link that has been a mystery in the field for decades," says lead author Joseph Holoshitz, M.D., professor of internal medicine and associate chief of research in the division of rheumatology at the U-M School of Medicine.

"We hope that this improved understanding will open the door to future design of drugs to treat this crippling disease and autoimmune disease in general."

The research appeared in The Journal of Immunology and was highlighted by Nature Reviews Rheumatology.

Rheumatoid arthritis is a chronic inflammatory disorder that damages the lining of joints and causes bone erosion, joint deformity and disability. The disease is an autoimmune disorder, characterized by the body's immune system mistakenly attacking the body's tissues.

Researchers have long studied the phenomenon of why certain versions of an inherited group of genes known as "human leukocyte antigen" (HLA) are associated with autoimmune disorders. One subset of these HLA genes that codes a protein sequence called "shared epitope" represents the most significant genetic risk factor for rheumatoid arthritis, affecting disease susceptibility and severity. However, until now, the reason for this strong link has been unclear.

A common theory in the field has been that the association between particular HLA genes and autoimmune diseases is a result of mistakenly identifying body tissues as foreign making the body the target of the immune system and setting off an attack on self-tissues, which results in disease.

The UMHS research challenges this long-held theory. The study shows, for the first time, how this subset of HLA genes causes arthritis by activating inflammation-causing cells, as well as bone-destroying cells (known as osteoclasts). This leads to severe arthritis and bone erosion.

"We showed how the shared epitope is directly triggering osteoclasts, the very cells that are responsible for joint destruction in people with the disease," says Holoshitz.

"Understanding these mechanisms at play could be a significant piece of future drug development. Because we now know the molecular mechanism that activates arthritis-causing cells, we have the potential to block that pathway with simple chemical compounds that could be used to treat rheumatoid arthritis and other diseases."


'/>"/>

Contact: Beata Mostafavi
bmostafa@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
2. Researchers discover promising prognostic marker for aggressive breast cancer
3. Researchers design a new imaging technique for identifying the age and sex of a corpse
4. Researchers map emotional intelligence in the brain
5. Researchers find that simple blood test can help identify trauma patients at greatest risk of death
6. Mayo Clinic researchers identify enzyme involved in deadly brain tumors
7. UNC researchers use luminescent mice to track cancer and aging in real-time
8. Gothenburg researchers make world top 10
9. Autism Researchers Surprised by Impaired Brain Connections
10. Researchers identify ways to improve quality of care measurement from electronic health records
11. Researchers identify genetic mutation for rare cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers uncover gene's role in rheumatoid arthritis, findings pave way for new treatments
(Date:12/9/2016)... ... , ... "I have gout, and I wanted to treat it naturally," said ... to relieve gout and pain caused by varicose veins. I drank it every morning ... relieved what VA doctors called the worst sinusitis case they'd seen and relieved gas, ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric ... patient safety. Only a few hospitals and facilities have earned this distinction. This ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 9, 2016 Research and Markets has ... report to their offering. ... The report forecasts the global optical transceiver market ... The report covers the present scenario and the ... calculate the market size, the report considers the revenue generated from ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
Breaking Medicine Technology: